Literature DB >> 18274787

Emergence of MRSA in positive blood cultures from patients with febrile neutropenia--a cause for concern.

Patrick G Morris1, Tidi Hassan, Mairead McNamara, Astrid Hassan, Rebecca Wiig, Liam Grogan, Oscar S Breathnach, Edmond Smyth, Hilary Humphreys.   

Abstract

GOALS OF WORK: Febrile neutropenia (FN) causes considerable morbidity in patients on cytotoxic chemotherapy. Recently, there has been a trend towards fewer Gram-negative and more Gram-positive infections with increasing antibiotic resistance. To assess these patterns, data from a supra-regional cancer centre in Ireland were reviewed. PATIENTS AND METHODS: A 5-year review of all positive blood cultures in patients undergoing anti-cancer chemotherapy was carried out. MAIN
RESULTS: Eight hundred and ninety-four patients were reviewed. The mean incidence of FN was 64.2 cases per year. Eight hundred and forty-six blood culture specimens were taken and 173 (20.4%) were culture positive. The isolated organisms were Gram positive (71.1%), Gram negative (27.8%) and fungal (1.1%). Of the Gram-positive organisms, 75.6% were staphylococci. Of these, 67.8% were coagulase-negative staphylococci and 30.1% were Staphylococci aureus. Amongst the S. aureus, 89.3% were methicillin-resistant (MRSA). Vancomycin-resistant enterococci were not identified as a cause of positive blood cultures.
CONCLUSIONS: Amongst patients with cancer who develop FN in our hospital, Gram-positive bacteria account for the largest proportion. The high proportion of MRSA as a cause of positive blood cultures is of concern.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18274787     DOI: 10.1007/s00520-007-0398-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  20 in total

1.  Epidemiology of MRSA: the North/South study of MRSA in Ireland 1999.

Authors:  P McDonald; E Mitchell; H Johnson; A Rossney; H Humphreys; G Glynn; M Burd; D Doyle; R McDonnell
Journal:  J Hosp Infect       Date:  2003-06       Impact factor: 3.926

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.

Authors:  Mical Paul; Sara Borok; Abigail Fraser; Liat Vidal; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2005-02-18       Impact factor: 5.790

Review 4.  Management of fever in patients with cancer and treatment-induced neutropenia.

Authors:  P A Pizzo
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

5.  Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.

Authors:  E González-Barca; A Fernández-Sevilla; J Carratalá; A Grañena; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

6.  Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia.

Authors:  P F Smith; M C Birmingham; G A Noskin; A K Meagher; A Forrest; C R Rayner; J J Schentag
Journal:  Ann Oncol       Date:  2003-05       Impact factor: 32.976

Review 7.  Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients.

Authors:  M Paul; S Borok; A Fraser; L Vidal; M Cohen; L Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

8.  Increasing incidence of Gram-positive sepsis in cancer patients.

Authors:  P A Pizzo; S Ladisch; R M Simon; F Gill; A S Levine
Journal:  Med Pediatr Oncol       Date:  1978

9.  A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special reference to anaerobes.

Authors:  P Mathur; R Chaudhry; L Kumar; A Kapil; B Dhawan
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

10.  Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.

Authors:  Rosy Reynolds; Nicola Potz; Melissa Colman; Andrea Williams; David Livermore; Alasdair MacGowan
Journal:  J Antimicrob Chemother       Date:  2004-05-05       Impact factor: 5.790

View more
  16 in total

1.  Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network.

Authors:  Jordi Rello; Cristina Sarda; Djamel Mokart; Kostoula Arvaniti; Murat Akova; Alexis Tabah; Elie Azoulay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-09       Impact factor: 3.267

2.  Increasing prevalence of nasal and rectal colonization with methicillin-resistant Staphylococcus aureus in children with cancer.

Authors:  Ashok Srinivasan; Steven E Seifried; Liang Zhu; Deo K Srivastava; Rosalie Perkins; Jerry L Shenep; Matthew J Bankowski; Randall T Hayden
Journal:  Pediatr Blood Cancer       Date:  2010-09-09       Impact factor: 3.167

3.  Which Multidrug-Resitant Bacteria are Emerging in Patients with Hematological Malignancies?: One-Year Report.

Authors:  Habip Gedik; Funda Şimşek; Taner Yıldırmak; Arzu Kantürk; Demet Aydın; Naciye Demirel; Osman Yokuş; Deniz Arıca
Journal:  Indian J Hematol Blood Transfus       Date:  2014-05-14       Impact factor: 0.900

4.  Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.

Authors:  Ajay Gupta; Mansher Singh; Harkirat Singh; Lalit Kumar; Atul Sharma; Sameer Bakhshi; Vinod Raina; Sanjay Thulkar
Journal:  Med Oncol       Date:  2009-10-15       Impact factor: 3.064

5.  The outcome of non-carbapenem-based empirical antibacterial therapy and VRE colonisation in patients with hematological malignancies.

Authors:  H Gedik; T Yildirmak; F Simsek; A Kanturk; D Aydýn; D Anca; O Yokus; N Demirel
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

Review 6.  Management of febrile neutropenia in the era of bacterial resistance.

Authors:  Sehnaz Alp; Murat Akova
Journal:  Ther Adv Infect Dis       Date:  2013-02

7.  Using antimicrobial adjuvant therapy in cancer treatment: a review.

Authors:  Kenneth Alibek; Aliya Bekmurzayeva; Assel Mussabekova; Bolat Sultankulov
Journal:  Infect Agent Cancer       Date:  2012-11-20       Impact factor: 2.965

8.  Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients.

Authors:  Elif Sahin Horasan; Gulden Ersoz; Anil Tombak; Naci Tiftik; Ali Kaya
Journal:  Med Sci Monit       Date:  2011-05

9.  Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry.

Authors:  Felix Keil; George L Daikos; Athanasios Skoutelis; Jose Ignacio Barranco Dominguez; Rashidkhan Pathan; Kamal Hamed
Journal:  Adv Ther       Date:  2015-08-04       Impact factor: 3.845

Review 10.  Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.

Authors:  Michael R Yeaman; Scott G Filler; Clint S Schmidt; Ashraf S Ibrahim; John E Edwards; John P Hennessey
Journal:  Front Immunol       Date:  2014-09-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.